Compound class:
Antibody
Comment: AMG820 is a monoclonal antibody targeting the receptor tyrosine kinase, CSF1R (Fms). It is claimed in patent WO2009026303 [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| A Phase 1/II clinical trial evaluating an AMG820 and pembrolizumab (approved anti-PD-1 antibody) is underway- see NCT02713529. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Anti-CSF1R antibodies prevent binding of the receptor's endogenous ligand CSF1 (or M-CSF). This action reduces monocyte infiltration into tumours and inhibits the acumulation of tumour-associated macrophages (TAMs). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02713529 | Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | Phase 1/Phase 2 Interventional | Amgen | ||
